Basisonkologie in der komplementären Praxis

Zusammenfassung

Die komplementäre Onkologie bietet eine unüberschaubare Zahl diagnostischer und therapeutischer Möglichkeiten. Die Anwender müssen daher im ärztlichen Alltag im Rahmen persönlicher Erfahrung und wissenschaftlich belastbarer Daten aus Epidemiologie, Grundlagenforschung und Therapie einen schwierigen Weg für den Patienten ebnen. Die Diskussionen mit konventionellen Onkologen zeigen noch zu häufig ungerechtfertigt breite Ablehnung komplementärer Methoden. Zwischen guten Daten einiger Verfahren und einem Abgrenzen weniger wertvoller Verfahren gilt es, eine individuell optimale Therapie für den Krebskranken zu finden und ihn gleichzeitig vor allzu Alternativem zu schützen. Für den begleitenden Hausarzt ist dieser Artikel möglicherweise ein kleiner Leitfaden.

Abstract

The complementary oncology offers a vast number of diagnostic and therapeutic options. The user must therefore in daily medical practice in the context of personal experience and scientifically robust data from epidemiology, basic research and therapy pave a difficult way for the patient. Discussions with conventional oncologists still show too often unjustifiably broad rejection of complementary methods. There is some good data between processes and delimiting a less valuable method of finding individually optimal therapy for cancer patients and to protect it from too alternative. For the accompanying family doctor this article may be a small guide.

Schlüsselwörter

Komplementäre Onkologie - Orthomolekulare Medizin - Hyperthermie - Ernährung - Mistel

Keywords

Complementary oncology - orthomolecular medicine - hyperthermia - nutrition - mistle toe

• Literatur


Die Literaturliste finden Sie im Internet unter: www.thieme-connect.de/ejournals
• 1 Walraven I, Riet E, Stehouwer CDA et al High proinsulin levels are independently associated with 20-year cancer mortality. The Hoorn study Presentation. Poster Nr. 234 bei 49. EASD-Kongress 2013 in Barcelona
• 2 Esposito K, Chiodini P, Colao A et al Metabolic Syndrome and Risk of Cancer − A systematic review and meta-analysis. Diabetes Care 2012; 35: 2402-2411
• 3 Gröber U, Mücke R, Adamietz IA et al Komplementärer Einsatz von Antioxidanzien und Mikronährstoffen in der Onkologie. Update 2013. Onkologe 2013; 19: 136-143
• 4 Schwaab J, Horisberger K, Erben P. Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011; 11: 363
• 5 Libby G, Donnelly LA, Donnan PT et al New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes care 2009; 32: 1620-1625
• 6 Pantuck AJ, Zomorodian N, Rettig M et al Long term follow up of phase 2 study of pomegranate juice for men with prostate cancer shows durable prolongation of PSA doubling time. J Urology 2009; 181: 295
• 7 Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality amoung US adults. Arch Intern Med 2008; 168: 404-410
• 8 Peters U, Takata Y. Selenium and the prevention of prostate and colorectal cancer. Molecular Nutrition & Food Research 2008; 52: 1261-1272
• 9 Mücke R, Schomburg L, Büntzel J. Komplementärer Seleneinsatz in der Onkologie. Onkologe 2010; 16: 181-186
• 10 Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 2004; 93: 320-327
• 11 Asfour IA, El-Tehewi MM, Ahmed MH. High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin’s lymphoma. Biol Trace Elem Res 2009; 127: 200-210
• 12 Lin YS, Lin LC, Lin SW. Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow- up of a double-blind randomized study with subgroup analysis. Laryngoscope 2009; 119: 1348-1352
• 13 Lappe JM, Travers-Gustafson D, Davies KM et al Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586-1591
• 14 Churilla TM, Brereton HD, Klem M. Vitamin D deficiency is widespread in cancer patients and correlates with advanced stage disease: a community oncology experience. Nutr Cancer 2012; 64: 521-525
• 15 Drake MT, Maurer MJ, Link BK. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28: 4191-4198
• 16 Gorham ED, Garland CF, Garland FC. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007; 32: 210-216
• 17 Goodwin PJ, Ennis M, Pritchard KI. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-3763
• 18 Schilling S. Epidemic vitamin D deficiency among patients in an elderly care rehabilitation facility. Dtsch Arztebl Int 2012; 109: 33-38
• 19 Santini D, Galluzzo S, Vincenzi B. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 2010; 21: 185-186
• 20 Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29: e81-e82
• 21 Prieto-Alhambra D, Javaid MK, Servitja S. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospectiv cohort study. Breast Cancer Res Treat 2011; 125: 869-878
• 22 Khan QJ, Reddy PS, Kimler BF. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119: 111-118
• 23 Roffe L, Schmidt K, Ernst E. Efficacy of Coenzyme Q10 for Improved Tolerability of Cancer Treatments: A Systematic Review. J Clin Oncol 2004; 22: 4418-4424
• 24 Konklin KA. Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity. Integr Cancer Ther 2005; 4: 110-130
• 25 Hall MN, Chavarro JE, Lee IM et al A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer Epidemiol Biomarkers Prev 2008; 17: 1136-1143
• 26 Colomer R, Moreno-Nogueira JM, García-Luna PP et al N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 2007; 97: 823-831
• 27 Zhang XH, Ma J, Smith-Warner SA et al Vitamin B6 and colorectal cancer: Current evidence and future directions. World J Gastroenterol 2013; 19: 1005-1010
• 28 Jin HW, Flatters SJ, Xiao WH. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008; 210: 229-237
• 29 Kraft M, Kraft K, Gärtner S et al L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) − a randomized multicentre trial. Nutr J 2012; 11: 52
• 30 Gröber U. Neuroenhancement mit α-Liponsäure. ZKM 2012; 1: 45-49
• 31 Glaudemans B, Knoers NV, Hoenderop JG et al New molecular players facilitating Mg 2+ reabsorption in the distal convoluted tubule. Kidney Int 2010; 77: 17-22
• 32 Vormann J. Physiologie und Pathophysiologie von Magnesium. Schw Zeitschr Ernährungsmed 2010; 1: 8-13
• 33 Chen Q, Espey MG, Sun AY et al Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci 2008; 105: 11105-11109
• 34 Gröber U, Hübner J, Holzhauer P. Vitamin C in der komplementären Onkologie. Onkologe 2010; 16: 303-313
• 35 Nechuta S, Lu W, Chen Z. Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 262-271
• 36 Vollbracht C, Schneider B, Leendert V. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2011; 25: 983-990
• 37 Tröger W, Ždrale Z, Stanković N et al Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer: Basic and Clinical Research 2012; 6: 173-180
• 38 Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 2010; 103: 1545-1557
• 39 Killian PH, Kronski E, Michalik K et al Curcumin Inhibits Prostate Cancer Metastasis in vivo by Targeting the Inflammatory Cytokines CXCL1 and -2. Carcinogenesis 2012; 33: 2507-2519
• 40 Sung B, Kunnumakkara AB, Sethi G et al Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8: 959-970
• 41 Hayun R. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leuk Lymphoma 2009; 50: 625-632
• 42 Sinha D, Biswas J, Sung B et al Chemopreventive and Chemotherapeutic Potential of Curcumin in Breast Cancer. Current Drug Targets 2012; 13: 1799-1819
• 43 Nakachi K, Suemasu K, Suga K et al Influence of Drinking Green Tea on Breast Cancer Malignancy among Japanese Patients. Jpn J Cancer Res 1998; 89: 254-261
• 44 Sartippour MR, Shao ZM, Heber D et al Green Tea Inhibits Vascular Endothelial Growth Factor (VEGF) Induction in Human Breast Cancer Cells. J Nutr 2002; 132: 2307-2311
• 45 Slivova V, Zaloga G, DeMichele SJ et al Green Tea Polyphenols Modulate Secretion of Urokinase Plasminogen Activator (uPA) and Inhibit Invasive Behavior of Breast Cancer Cells. Nutrition and Cancer 2005; 52: 66-73
• 46 Liu FT, Agrawal SG, Movasaghi Z et al Dietary flavonoids inhibit the anti-cancer effects of the proteasome inhibitor Bortezomib. Blood 2008; 112: 3540-3541
• 47 Amin AR, Khuri FR, Chen ZG et al Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res 2009; 2: 538-545
• 48 Milligan SA, Burke P, Coleman DT et al The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 2009; 15: 4885-4894
• 49 Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. European Urology 2008; 54: 472-473
• 50 Böker DK, Winking M. Die Rolle von Boswellia-Säuren in der Therapie maligner Gliome. Dt Ärztebl 1997; 94: A-1197-1199
• 51 Kirste S, Trier M, Wehrle SJ et al Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors. Cancer 2011; 117: 3788-3795
• 52 Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: Bench to bedside. Carcinogenesis 2006; 45: 436-442
• 53 JM Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade−Eicosanoids, Cyclooxygenases, and Lipoxygenases − As an Adjunct in Cancer Therapy. Integr Cancer Ther 2002; 1: 7-37
• 54 Kallifatidis G, Rausch V, Baumann B et al Sulforaphane targets pancreatic tumor-initiating cells by NF-κB-induced anti-apoptotic signaling. GUT 2009; 58: 949-963
• 55 Beuth J. Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction?. Integr Cancer Ther 2008; 7: 311-316
• 56 Gebauer F, Micheel B, Stauder G et al Proteolytic Enzymes Modulate the Adhesion Molecule CD44 on Malignant Cells in Vitro. Int. J. Immunotherapy 1997; 13: 111-119
• 57 Stoll G. Thymuspeptide in der Onkologie. Z Onkol 1999; 31: 1-7
• 58 Kindler M. Factor AF2 als Begleitmaßnahme zur Chemotherapie − myeloprotektive und antiemetische Wirkungen. Z Onkol 1997; 29: 7-10
• 59 Matsumoto S. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis − A epitope expression on tumour cells. British Journal of Cancer 2002; 86: 161-167
• 60 Li B, Cao F, Zhu Q et al Perioperative Cimetidine Administration Improves Systematic Immune Response and Tumor Infiltrating Lymphocytes in Patients with Colorectal Cancer. Hepatogastroenterology 2013; 60: 244-247
• 61 Lefranc F, Yeaton P, Brotchi J et al Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma. Int J Oncol 2006; 28: 1021-1030
• 62 Calderwood SK, Murshid A, Gong J. Heat Shock Proteins: Conditional Mediators of Inflammation in Tumor Immunity. Front Immunol 2012; 3: 75
• 63 Multhoff G, Radons J. Radiation, Inflammation, and Immune Responses in Cancer. Front Oncol 2012; 2: 58
• 64 Wust P, Hildebrandt B, Sreenivasa G et al Hyperthermia in combined treatment of cancer. The Lancet Oncology 2002; 3: 487-497
• 65 Hager ED, Dziambor H, Höhmann D et al Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001; 11: 57-63
• 66 Bojko P, Schimmel G, Bosse D et al Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors. Onkologie 2012; 35: 35-38
• 67 Mills E, Wu P, Seely D et al Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. Journal of Pineal Research 2005; 39: 360-366
• 68 Harris RE, Beebe-Donk J, Doss H et al Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade. Oncology Reports 2005; 13: 559-583
• 69 Rothwell PM. Aspirin in Prevention of Sporadic Colorectal Cancer: Current Clinical Evidence and Overall Balance of Risks and Benefits. Prospects for Chemoprevention of Colorectal Neoplasia: Recent Results in Cancer Research 2013 191. 121-142
• 70 Potter GA, Burke MD. Salvestrols − Natural Products with Tumor Selective Activity. J Orthomol Med 2006; 21: 34-36
• 71 Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989-994
• 72 Lever JR. Opioid Receptors and Ligands: Targets for Cancer Imaging and Therapy. Med Chem 2012; 2: 142-147
• 73 Hagenbeck C, Krawcyk N, Melcher C et al Zirkulierende Tumorzellen − bereits klinische Routine oder noch Forschungsobjekt?. Deutsche Zeitschrift für Onkologie 2013; 45: 55-61